Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 31;18(1):1865774.
doi: 10.1080/21645515.2020.1865774. Epub 2021 Feb 5.

Coronavirus (SARS-CoV-2): a systematic review for potential vaccines

Mihir Bhatta  1 , Srijita Nandi  1 , Shanta Dutta  2 , Malay Kumar Saha  1
Affiliations

Coronavirus (SARS-CoV-2): a systematic review for potential vaccines

Mihir Bhatta et al. Hum Vaccin Immunother. .

Abstract

COVID-19 is an international public health emergency in need of effective and safe vaccines for SARS-CoV-2. A systematic review has been done to analyze the availability, development and status of new COVID-19 vaccine candidates as well as the status of vaccines for other diseases that might be effective against SARS-CoV-2 infection. PubMed, MEDLINE, EMBASE, Science Direct, Google Scholar, Cochrane library, ClinicalTrials.gov, Web of Science and different trial registries were searched for currently available and probable future vaccines. Articles and ongoing clinical trials are included to ascertain the availability and developmental approaches of new vaccines that could limit the present and future outbreaks. Pharmaceutical companies and institutions are at different stages of developing new vaccines, and extensive studies and clinical trials are still required.

Keywords: SARS-CoV-2; clinical trial; coronavirus; covid-19; vaccine candidates; vaccine development.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA diagram showing literature search for eligible articles.
Figure 2.
Figure 2.
Schematic illustration that depicts the strategies of development of new vaccine candidates against coronavirus or SARS-CoV-2.
Figure 3.
Figure 3.
Timeline cascade showing the development of two popular vaccines against Polio and Ebola. However, still there are no vaccine available for SARS-CoV-1 for approximately more than 15 years and MERS for more than 6 years of first recognized case. Similar to the other betacoronavirusus, no vaccines are still available for SARS-CoV-2, which is also a betacoronavirusus ‘only’ after 14 months of first recognized case.
See this image and copyright information in PMC

References

    1. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–18. - PMC - PubMed
    1. Fauci AS, Lane HC, Redfield RR.. Covid-19 - navigating the uncharted. N Engl J Med. 2020;382(13):1268–69. doi:10.1056/NEJMe2002387. - DOI - PMC - PubMed
    1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74. doi:10.1016/S0140-6736(20)30251-8. - DOI - PMC - PubMed
    1. Chakraborty D, Debnath F, Biswas S, Bhatta M, Ganguly S, Deb AK, Saha MK, Dutta S. Exploring repurposing potential of existing drugs in the management of COVID-19 epidemic: a critical review. J Clin Med Res. 2020;12(8):463–71. doi:10.14740/jocmr4241. - DOI - PMC - PubMed
    1. Cavanagh D. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol. 2003;32(6):567–82. doi:10.1080/03079450310001621198. - DOI - PMC - PubMed

Publication types

LinkOut - more resources